| ID | 1149 |
| Name of the vaccine | OmniHib |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 2 months to 5 years |
| Description of the vaccine | Haemophilus b conjugate vaccine (Tetanus toxoid conjugate) (PRP-T). |
| Name of the manufacturer | Pasteur Mérieux Serums & Vaccins S. A. |
| Name of the manufacturing country | France |
| Year of manufacture | 1993 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Whitish suspension |
| Dosage | Four dose series (0.5 ml each). Primary series: One dose at 2, 4, and 6 months.
Booster: One dose at 15 through 18 months. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Prevention of invasive diseases caused by diphtheria, tetanus, pertussis and H influenzae type b. |
| Export | Distributed by - SmithKline Beecham Pharmaceuticals |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | Also for diphtheria, tetanus and pertussis. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.cdc.gov/mmwr/preview/mmwrhtml/00044501.htm |
| Other name | NA |
| Additional Links | https://www.rxlist.com/dtp-drug.htm#description
|